Potential of epigenetic events in human thyroid cancer

Chornokur, 2015, Common genetic variation in cellular transport genes and epithelial ovarian cancer (EOC) risk, PLoS One, 10, 10.1371/journal.pone.0128106 Singh, 2013, The interactions of microRNA and epigenetic modifications in prostate cancer, Cancers (Basel), 5, 998, 10.3390/cancers5030998 Costa-Guda, 2014, Genetic and epigenetic changes in sporadic endocrine tumors: parathyroid tumors, Mol Cell Endocrinol, 386, 46, 10.1016/j.mce.2013.09.005 Baylin, 2005, DNA methylation and gene silencing in cancer, Nat Clin Pract Oncol, 2, S4, 10.1038/ncponc0354 Murata, 2002, Detection of underlying characteristics of nuclear chromatin patterns of thyroid tumor cells using texture and factor analyses, Cytometry, 49, 91, 10.1002/cyto.10162 Russo, 2011, Epigenetics of thyroid cancer and novel therapeutic targets, J Mol Endocrinol, 46, R73, 10.1530/JME-10-0150 Weinhold, 2006, Epigenetics: the science of change, Environ Health Perspect, 114, A160, 10.1289/ehp.114-a160 Turner, 2009, Epigenetic responses to environmental change and their evolutionary implications, Philosop. Trans. R Soc B, 364, 3403, 10.1098/rstb.2009.0125 Sharma, 2010, Epigenetics in cancer, Carcinogenesis, 31, 27, 10.1093/carcin/bgp220 Kronholm, 2015, Epigenetic mutations can both help and hinder adaptive evolution, Mol Ecol Berdasco, 2010, Aberrant epigenetic landscape in cancer: how cellular identity goes awry, Dev. Cell, 19, 698, 10.1016/j.devcel.2010.10.005 Li, 2013, Epigenetic regulation of multiple tumor-related genes leads to suppression of breast tumorigenesis by dietary genistein, PLoS One, 8, e54369, 10.1371/journal.pone.0054369 Faam, 2015, Epigenetic modifications in human thyroid cancer, Biomed Rep, 3, 3, 10.3892/br.2014.375 Xing, 2013, Molecular pathogenesis and mechanisms of thyroid cancer, Nat Rev Cancer, 13, 184, 10.1038/nrc3431 Jansen, 2013, Hallmarks of aromatase inhibitor drug resistance revealed by epigenetic profiling in breast cancer, Cancer Res, 73, 6632, 10.1158/0008-5472.CAN-13-0704 Antonelli, 2012, New targeted therapies for anaplastic thyroid cancer, Anticancer Agents Med Chem, 12, 87, 10.2174/187152012798764732 Munoa, 2015, The epigenetic regulation of the opioid system: new individualized prompt prevention and treatment strategies, J Cell Biochem To, 2015, DNA methylation within transcribed regions, Plant Physiol, 10.1104/pp.15.00543 Robertson, 2001, DNA methylation, methyltransferases, and cancer, Oncogene, 20, 3139, 10.1038/sj.onc.1204341 Fujimura, 2008, Germinal center B-cell-associated DNA hypomethylation at transcriptional regions of the AID gene, Mol. Immunol., 45, 1712, 10.1016/j.molimm.2007.09.023 Zhang, 2013, Decreased PADI4 mRNA association with global hypomethylation in hepatocellular carcinoma during HBV exposure, Cell Biochem Biophys, 65, 187, 10.1007/s12013-012-9417-3 Ehrlich, 2009, DNA hypomethylation in cancer cells, Epigenomics, 1, 239, 10.2217/epi.09.33 Wei, 2002, Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers, Clin Cancer Res, 8, 2246 Deaton, 2011, CpG islands and the regulation of transcription, Genes Dev, 25, 1010, 10.1101/gad.2037511 Hong, 2006, Promoter hypermethylation of the p16 gene and loss of its protein expression is correlated with tumor progression in extrahepatic bile duct carcinomas, Arch Pathol Lab Med, 130, 33, 10.5858/2006-130-33-PHOTPG Hu, 2006, Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer, Int J Cancer, 119, 2322, 10.1002/ijc.22110 Guan, 2008, Hypermethylation of the DNA mismatch repair gene hMLH1 and its association with lymph node metastasis and T1799A BRAF mutation in patients with papillary thyroid cancer, Cancer, 113, 247, 10.1002/cncr.23548 Bodoor, 2014, DNA hypermethylation of cell cycle (p15 and p16) and apoptotic (p14, p53, DAPK and TMS1) genes in peripheral blood of leukemia patients, Asian Pac J Cancer Prev, 15, 75, 10.7314/APJCP.2014.15.1.75 Sharma, 2010, Hypermethylation of carcinogen metabolism genes, CYP1A1, CYP2A13 and GSTM1 genes in head and neck cancer, Oral Dis, 16, 668, 10.1111/j.1601-0825.2010.01676.x DesRochers, 2012, The 3D tissue microenvironment modulates DNA methylation and E-cadherin expression in squamous cell carcinoma, Epigenetics, 7, 34, 10.4161/epi.7.1.18546 Zhang, 2013, MicroRNA role in thyroid cancer pathogenesis, Front Biosci (Landmark Ed), 18, 734, 10.2741/4135 Smith, 2013, DNA methylation: roles in mammalian development, Nat Rev Genet, 14, 204, 10.1038/nrg3354 Sharp, 2011, DNA methylation profiles of human active and inactive X chromosomes, Genome Res, 21, 1592, 10.1101/gr.112680.110 Acevedo, 2015, Age-associated DNA methylation changes in immune genes, histone modifiers and chromatin remodeling factors within 5 years after birth in human blood leukocytes, Clin Epigenetics, 7, 34, 10.1186/s13148-015-0064-6 Devaney, 2013, Identification of novel DNA-methylated genes that correlate with human prostate cancer and high-grade prostatic intraepithelial neoplasia, Prostate Cancer Prostatic Dis, 16, 292, 10.1038/pcan.2013.21 Shigeyasu, 2015, Clinical significance of MLH1 methylation and CpG island methylator phenotype as prognostic markers in patients with gastric cancer, PLoS One, 10, 10.1371/journal.pone.0130409 Kobayashi, 2011, DNA methylation profiling reveals novel biomarkers and important roles for DNA methyltransferases in prostate cancer, Genome Res, 21, 1017, 10.1101/gr.119487.110 Matsuda, 2015, Absolute quantification of acetylation and phosphorylation of the histone variant H2AX upon ionizing radiation reveals distinct cellular responses in two cancer cell lines, Radiat Environ Biophys, 10.1007/s00411-015-0608-3 Bartova, 2008, Histone modifications and nuclear architecture: a review, J Histochem Cytochem, 56, 711, 10.1369/jhc.2008.951251 Bannister, 2011, Regulation of chromatin by histone modifications, Cell Res., 21, 381, 10.1038/cr.2011.22 Campbell, 2013, Altered histone modifications in cancer, Adv Exp Med Biol, 754, 81, 10.1007/978-1-4419-9967-2_4 House, 2014, Chromatin modifications and DNA repair: beyond double-strand breaks, Front Genet, 5, 296, 10.3389/fgene.2014.00296 Sawan, 2010, Histone modifications and cancer, Adv. Genet., 70, 57, 10.1016/B978-0-12-380866-0.60003-4 Chen, 2010, Histone modifications and chromatin organization in prostate cancer, Epigenomics, 2, 551, 10.2217/epi.10.31 Struhl, 1998, Histone acetylation and transcriptional regulatory mechanisms, Genes Dev, 12, 599, 10.1101/gad.12.5.599 Zhang, 2014, Histone deacetylation of NIS promoter underlies BRAF V600E-promoted NIS silencing in thyroid cancer, Endocr Relat Cancer, 21, 161, 10.1530/ERC-13-0399 West, 2014, New and emerging HDAC inhibitors for cancer treatment, J Clin Invest, 124, 30, 10.1172/JCI69738 Kawasaki, 2008, CpG island methylator phenotype-low (CIMP-low) colorectal cancer shows not only few methylated CIMP-high-specific CpG islands, but also low-level methylation at individual loci, Mod Pathol, 21, 245, 10.1038/modpathol.3800982 Weisenberger, 2015, Association of the colorectal CpG island methylator phenotype with molecular features, risk factors, and family history, Cancer Epidemiol Biomarkers Prev, 24, 512, 10.1158/1055-9965.EPI-14-1161 Teschendorff, 2009, An epigenetic signature in peripheral blood predicts active ovarian cancer, PLoS One, 4, e8274, 10.1371/journal.pone.0008274 Feng, 2014, SOCS3 promoter hypermethylation is a favorable prognosticator and a novel indicator for G-CIMP-positive GBM patients, PLoS One, 9, e91829, 10.1371/journal.pone.0091829 Goel, 2007, The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer, Gastroenterology, 132, 127, 10.1053/j.gastro.2006.09.018 Wajed, 2001, DNA methylation: an alternative pathway to cancer, Ann Surg, 234, 10, 10.1097/00000658-200107000-00003 Shen, 2002, DNA methylation and environmental exposures in human hepatocellular carcinoma, J Natl Cancer Inst, 94, 755, 10.1093/jnci/94.10.755 Toyota, 1999, Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype, Cancer Res, 59, 5438 Roman-Gomez, 2006, CpG island methylator phenotype redefines the prognostic effect of t(12;21) in childhood acute lymphoblastic leukemia, Clin Cancer Res, 12, 4845, 10.1158/1078-0432.CCR-05-2592 Suzuki, 2006, Exclusive mutation in epidermal growth factor receptor gene, HER-2, and KRAS, and synchronous methylation of nonsmall cell lung cancer, Cancer, 106, 2200, 10.1002/cncr.21853 Marsit, 2006, Examination of a CpG island methylator phenotype and implications of methylation profiles in solid tumors, Cancer Res, 66, 10621, 10.1158/0008-5472.CAN-06-1687 Strathdee, 2001, Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes, Am J Pathol, 158, 1121, 10.1016/S0002-9440(10)64059-X Kikuchi, 2013, Aberrantly methylated genes in human papillary thyroid cancer and their association with BRAF/RAS mutation, Front Genet, 4, 271, 10.3389/fgene.2013.00271 Choi, 2014, B-RafV600E inhibits sodium iodide symporter expression via regulation of DNA methyltransferase 1, Exp. Mol. Med., 46, e120, 10.1038/emm.2014.68 Teodoridis, 2008, CpG island methylator phenotype (CIMP) in cancer: causes and implications, Cancer Lett, 268, 177, 10.1016/j.canlet.2008.03.022 Tanemura, 2009, CpG island methylator phenotype predicts progression of malignant melanoma, Clin Cancer Res, 15, 1801, 10.1158/1078-0432.CCR-08-1361 Huang, 2009, Identification of candidate epigenetic biomarkers for ovarian cancer detection, Oncol Rep, 22, 853 Witte, 2014, Pan-cancer patterns of DNA methylation, Genome Med, 6, 66, 10.1186/s13073-014-0066-6 Koukoura, 2014, DNA methylation profiles in ovarian cancer: implication in diagnosis and therapy (Review), Mol Med Rep, 10, 3, 10.3892/mmr.2014.2221 Catalano, 2012, Epigenetics modifications and therapeutic prospects in human thyroid cancer, Front Endocrinol (Lausanne), 3, 40, 10.3389/fendo.2012.00040 Kondo, 2009, Epigenetic silencing of TTF-1/NKX2-1 through DNA hypermethylation and histone H3 modulation in thyroid carcinomas, Lab Invest, 89, 791, 10.1038/labinvest.2009.50 Hoque, 2005, Quantitative assessment of promoter methylation profiles in thyroid neoplasms, J Clin Endocrinol Metab, 90, 4011, 10.1210/jc.2005-0313 Schagdarsurengin, 2002, Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma, Cancer Res, 62, 3698 Alvarez-Nunez, 2006, PTEN promoter methylation in sporadic thyroid carcinomas, Thyroid, 16, 17, 10.1089/thy.2006.16.17 Cantley, 1999, New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway, Proc Natl Acad Sci USA, 96, 4240, 10.1073/pnas.96.8.4240 Xing, 2004, Early occurrence of RASSF1A hypermethylation and its mutual exclusion with BRAF mutation in thyroid tumorigenesis, Cancer Res, 64, 1664, 10.1158/0008-5472.CAN-03-3242 Qi, 2003, A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2, Nat Med, 9, 407, 10.1038/nm846 De Falco, 2007, RET/Papillary thyroid carcinoma oncogenic signaling through the Rap1 Small GTPase, Cancer Res., 67, 381, 10.1158/0008-5472.CAN-06-0981 Gao, 2006, Ras-associated protein-1 regulates extracellular signal-regulated kinase activation and migration in melanoma cells: two processes important to melanoma tumorigenesis and metastasis, Cancer Res, 66, 7880, 10.1158/0008-5472.CAN-06-0254 Wang, 2006, Rap1-Mediated activation of extracellular signal-regulated kinases by cyclic amp is dependent on the mode of Rap1 activation, Mol. Cell. Biol., 26, 2130, 10.1128/MCB.26.6.2130-2145.2006 Zhang, 2006, Identification of a putative tumor suppressor gene Rap1GAP in pancreatic cancer, Cancer Res, 66, 898, 10.1158/0008-5472.CAN-05-3025 Zhang, 2006, Rap1GAP inhibits tumor growth in oropharyngeal squamous cell carcinoma, Am J Pathol, 168, 585, 10.2353/ajpath.2006.050132 Nellore, 2009, Loss of Rap1GAP in papillary thyroid cancer, J Clin Endocrinol Metab, 94, 1026, 10.1210/jc.2008-1042 Tsygankova, 2007, Downregulation of Rap1GAP contributes to Ras transformation, Mol Cell Biol, 27, 6647, 10.1128/MCB.00155-07 Rodriguez-Rodero, 2013, DNA methylation signatures identify biologically distinct thyroid cancer subtypes, J Clin Endocrinol Metab, 98, 2811, 10.1210/jc.2012-3566 Puppin, 2011, Levels of histone acetylation in thyroid tumors, Biochem Biophys Res Commun, 411, 679, 10.1016/j.bbrc.2011.06.182 Borbone, 2011, Enhancer of zeste homolog 2 overexpression has a role in the development of anaplastic thyroid carcinomas, J Clin Endocrinol Metab, 96, 1029, 10.1210/jc.2010-1784 Liu, 2019, Long non-coding and coding RNA profiling using strand-specific RNA-seq in human hypertrophic cardiomyopathy, Sci Data, 6, 90, 10.1038/s41597-019-0094-6 Kumari, 2015, cncRNAs: Bi-functional RNAs with protein coding and non-coding functions, Semin. Cell Dev. Biol., 47-48, 40, 10.1016/j.semcdb.2015.10.024 Liu, 2018, Systematic analysis of long non-coding RNAs and mRNAs in the ovaries of Duroc pigs during different follicular stages using RNA sequencing, Int J Mol Sci, 19, 1722, 10.3390/ijms19061722 Xing, 2019, Genome-Wide identification of long non-coding RNAs responsive to Lasiodiplodia theobromae infection in Grapevine, Evol Bioinform Online, 15, 10.1177/1176934319841362 Derrien, 2012, The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression, Genome Res., 22, 1775, 10.1101/gr.132159.111 Charles Richard, 2018, Platforms for investigating LncRNA functions, Slas Technol, 23, 493, 10.1177/2472630318780639 Liu, 2015, Long noncoding RNA transcriptome of plants, Plant Biotechnol. J., 13, 319, 10.1111/pbi.12336 Carninci, 2005, The transcriptional landscape of the mammalian genome, Science, 309, 1559, 10.1126/science.1112014 Taft, 2007, The relationship between non-protein-coding dna and eukaryotic complexity, Bioessays: news and reviews in molecular, Cellular Develop Biol, 29, 288 Zhang, 2019, Long non-coding RNA and breast cancer, Technol Cancer Res Treat, 18, 10.1177/1533033819843889 Fernandes, 2019, Long non-coding RNAs in the regulation of gene expression: physiology and disease, Noncoding RNA, 5, 17 Wang, 2017, LncRNA structural characteristics in epigenetic regulation, Int J Mol Sci, 18, 2659, 10.3390/ijms18122659 De Majo, 2018, Chromatin remodelling and epigenetic state regulation by non-coding RNAs in the diseased heart, Non-Coding RNA Res, 3, 20, 10.1016/j.ncrna.2018.02.003 Romero-Barrios, 2018, Splicing regulation by long noncoding RNAs, Nucleic Acids Res., 46, 2169, 10.1093/nar/gky095 Huarte, 2015, The emerging role of lncRNAs in cancer, Nat. Med., 21, 1253, 10.1038/nm.3981 Tye, 2015, Could lncRNAs be the missing links in control of mesenchymal stem cell differentiation?, J. Cell. Physiol., 230, 526, 10.1002/jcp.24834 Yang, 2018, Analysis of LncRNA expression in cell differentiation, RNA Biol, 15, 413, 10.1080/15476286.2018.1441665 Islam Khan, 2019, Autophagy-Modulating long non-coding RNAs (LncRNAs) and their molecular events in cancer, Front Genet, 9, 750, 10.3389/fgene.2018.00750 Sun, 2018, MIR100 host gene-encoded lncRNAs regulate cell cycle by modulating the interaction between HuR and its target mRNAs, Nucleic Acids Res., 46, 10405, 10.1093/nar/gky696 Yu, 2018, lncRNA LINC01296 regulates the proliferation, metastasis and cell cycle of osteosarcoma through cyclin D1, Oncol. Rep., 40, 2507 Zhang, 2018, The long non-coding RNA SNHG1 attenuates cell apoptosis by regulating miR-195 and BCL2-Like protein 2 in human cardiomyocytes, Cell Physiol Biochem, 50, 1029, 10.1159/000494514 Zhou, 2018, The regulatory roles of lncRNAs in the process of breast cancer invasion and metastasis, Biosci Rep, 38, 10.1042/BSR20180772 Bin, 2018, Research progresses in roles of LncRNA and its relationships with breast cancer, Cancer Cell Int, 18, 179, 10.1186/s12935-018-0674-0 Fico, 2019, Long non-coding RNA in stem cell pluripotency and lineage commitment: functions and evolutionary conservation, Cell Mol Life Sci, 76, 1459, 10.1007/s00018-018-3000-z Cipolla, 2018, Long non-coding RNAs in multifactorial diseases: another layer of complexity, Noncoding RNA, 4, 13 Pstrąg, 2018, Thyroid cancers of follicular origin in a genomic light: in-depth overview of common and unique molecular marker candidates, Mol. Cancer, 17, 116, 10.1186/s12943-018-0866-1 Lan, 2015, Downregulation of long noncoding RNA NONHSAT037832 in papillary thyroid carcinoma and its clinical significance, Tumour Biol, 37, 6117, 10.1007/s13277-015-4461-4 You, 2018, Integrated analysis of long noncoding RNA interactions reveals the potential role in progression of human papillary thyroid cancer, Cancer Med, 7, 5394, 10.1002/cam4.1721 Qiu, 2019, Pathway analysis of a genome-wide association study on a long non-coding RNA expression profile in oral squamous cell carcinoma, Oncol. Rep., 41, 895 Lan, 2015, Genome-wide analysis of long noncoding RNA expression profile in papillary thyroid carcinoma, Gene, 569, 109, 10.1016/j.gene.2015.05.046 Yang, 2016, Long noncoding RNA are aberrantly expressed in human papillary thyroid carcinoma, Oncol Lett, 12, 544, 10.3892/ol.2016.4653 Wang, 2016, Identification of specific long non-coding RNA expression: profile and analysis of association with clinicopathologic characteristics and BRAF mutation in papillary thyroid cancer, Thyroid, 26, 1719, 10.1089/thy.2016.0024 Mahmoudian-Sani, 2019, Long non-coding RNAs in thyroid cancer: implications for pathogenesis, diagnosis, and therapy, Oncol Res Treat, 42, 136, 10.1159/000495151 Harapan, 2015, The role of microRNAs in the proliferation, differentiation, invasion, and apoptosis of trophoblasts during the occurrence of preeclampsia—A systematic review, Tzu Chi Med J, 27, 54, 10.1016/j.tcmj.2015.05.001 Li, 2013, MicroRNA expression profiles in differentiated thyroid cancer, a review, Int J Clin Exp Med, 6, 74 Hung, 2014, MicroRNAs in hepatocellular carcinoma: carcinogenesis, progression, and therapeutic target, Biomed Res Int Jansson, 2012, MicroRNA and cancer, Mol Oncol, 6, 590, 10.1016/j.molonc.2012.09.006 Nana-Sinkam, 2014, MicroRNA regulation of tumorigenesis, cancer progression and interpatient heterogeneity: towards clinical use, Genome Biol, 15, 445, 10.1186/s13059-014-0445-8 Zhang, 2007, microRNAs as oncogenes and tumor suppressors, Dev Biol, 302, 1, 10.1016/j.ydbio.2006.08.028 Calin, 2006, MicroRNA signatures in human cancers, Nat Rev Cancer, 6, 857, 10.1038/nrc1997 Allegra, 2012, new biomarkers in diagnosis, prognosis and treatment of cancer (review), Int J Oncol, 41, 1897, 10.3892/ijo.2012.1647 Samimi, 2013, MicroRNAs networks in thyroid cancers: focus on miRNAs related to the fascin, J Diabetes Metab Disord, 12, 31, 10.1186/2251-6581-12-31 Popovic, 2012, Emerging epigenetic targets and therapies in cancer medicine, Cancer Discov, 2, 405, 10.1158/2159-8290.CD-12-0076 Kafri, 1992, Developmental pattern of gene-specific dna methylation in the mouse embryo and germ line, Genes Dev, 6, 705, 10.1101/gad.6.5.705 Issa, 2000, CpG-island methylation in aging and cancer, Curr Top Microbiol Immunol, 249, 101 Liebner, 2011, Thyroid cancer: pathogenesis and targeted therapy, Ther Adv Endocrinol Metab, 2, 173, 10.1177/2042018811419889 Tsou, 2002, DNA methylation analysis: a powerful new tool for lung cancer diagnosis, Oncogene, 21, 5450, 10.1038/sj.onc.1205605 Suzuki, 2002, A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer, Nat Genet, 31, 141, 10.1038/ng892 Venkataraman, 1999, Restoration of iodide uptake in dedifferentiated thyroid carcinoma: relationship to human Na+/I-symporter gene methylation status, J Clin Endocrinol Metab, 84, 2449 Xing, 2003, Methylation of the thyroid-stimulating hormone receptor gene in epithelial thyroid tumors: a marker of malignancy and a cause of gene silencing, Cancer Res, 63, 2316 Provenzano, 2007, Increased iodine uptake in thyroid carcinoma after treatment with sodium butyrate and decitabine (5-Aza-dC), Otolaryngol Head Neck Surg, 137, 722, 10.1016/j.otohns.2007.07.030 Miasaki, 2008, Retinoic acid receptor beta2 re-expression and growth inhibition in thyroid carcinoma cell lines after 5-aza-2′-deoxycytidine treatment, J Endocrinol Invest, 31, 724, 10.1007/BF03346422 Kurkjian, 2008, DNA methylation: its role in cancer development and therapy, Curr Probl Cancer, 32, 187, 10.1016/j.currproblcancer.2008.08.002 Johnstone, 2002, Histone-deacetylase inhibitors: novel drugs for the treatment of cancer, Nat Rev Drug Discov, 1, 287, 10.1038/nrd772 Fuino, 2003, Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B, Mol Cancer Ther, 2, 971 Plumb, 2003, Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101, Mol Cancer Ther, 2, 721 Atadja, 2009, Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges, Cancer Lett, 280, 233, 10.1016/j.canlet.2009.02.019